GenSight Biologics announced the appointment of Sissel Rodahl as Senior Vice-President of Commercial Operations. Mrs. Rodahl will intensify the company's efforts to build a strong and adaptable commercial organization to secure the successful launch of LUMEVOQ in Europe, which is expected early 2023. She will be a member of the Executive Committee and report to the Chief Executive Officer.

Sissel Rodahl joins GenSight after more than 25 years in rare diseases and gene therapies, in a range of commercial leadership roles that brought her expanding responsibilities during her tenure at Serono, Merck KGaA, Shire, Raptor, Horizon and AveXis. She joined AveXis as one of the first people to build from scratch the multi-functional team that successfully launched Zolgensma, the first one-time gene therapy for the treatment of Spinal Muscular Atrophy (SMA). She had a key role in developing and executing the go-to-market strategy and in building the AveXis organization in Europe, the Middle East and Africa (EMEA), which was later acquired by Novartis.

Most recently Sissel Rodahl served as Vice President for Novartis Gene Therapies where she successfully led the launch of Zolgensma for a cluster of 15 countries in Western Europe.